卒中后抑郁(PSD)是一种以情绪低落、兴趣丧失、自我评价降低、食欲下降、失眠等为主要症状的慢性疾病,是脑卒中患者常见的并发症之一,同时也是导致脑卒中患者残疾和死亡的主要原因之一。根据最新国外相关研究显示,PSD可增加20%~50%的脑卒中患者再住院率和死亡率,缩短生存时间。而据我国相关研究发现,在我国脑卒中患者中约有20%~30%会发生PSD,这意味着PSD已成为影响我国脑卒中患者生活质量的重要因素。本文通过对PSD的发病机制、治疗方面的最新研究进展作一综述,以期为相关领域的研究提供参考。Post-stroke depression (PSD) is a chronic disease characterized by symptoms such as low mood, loss of interest, reduced self-esteem, decreased appetite, and insomnia. PSD is one of the common complications in stroke patients and significantly impacts their quality of life. It is one of the main causes leading to disability and death among stroke patients. International studies have shown that PSD can increase the rate of rehospitalization and mortality by 20% to 50% in stroke patients, and it can also shorten their survival time. Studies in China have also found that about 20% to 30% of stroke patients may develop PSD, making it a significant factor affecting the quality of life of stroke patients in our country. This article primarily reviews the latest research progress in the pathogenesis and treatment of PSD, aiming to provide a reference for clinicians.
精神分裂症作为21世纪精神卫生工作的重点,同时作为临床上常见的较为严重的精神障碍之一,一直是临床重点管理及防控的工作内容。精神分裂症的治疗也作为各项研究关注的重点。神经递质以及脑源性神经营养因子的异常作为精神分裂症发病机制中重要环节也常被人关注。本文综述了无抽搐电休克(modified electroconvulsive therapy, MECT)联合二代抗精神病药物治疗精神分裂症的疗效及其对神经递质、脑源性神经营养因子(BDNF)的影响等,从多个方面探讨并总结目前精神分裂症治疗的进展。As the focus of mental health work in the 21st century, and as one of the more serious mental disorders commonly seen in clinical practice, schizophrenia has always been the focus of clinical management, prevention and control. The treatment of schizophrenia has also been the focus of various studies. Abnormalities in neurotransmitters and brain-derived neurotrophic factors are also often considered an important part of the pathogenesis of schizophrenia. This article reviews the efficacy of modified electroconvulsive therapy (MECT) combined with second-generation antipsychotic drugs in the treatment of schizophrenia and its effects on neurotransmitters and brain-derived neurotrophic factor (BDNF). It explores and summarizes the current progress in the treatment of schizophrenia from multiple perspectives.
